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Background: Unipolar depression might be characterized by a 'low-thyroid function syndrome'.
To our knowledge, this is the first study which explores the possible relationship of DSM-IV
depressive subtypes and the medium term outcome, with thyroid function.
Methods: Material: Thirty major depressive patients (DSM-IV) aged 21–60 years and 60 control
subjects were included. Clinical Diagnosis: The SCAN v 2.0 and the IPDE were used. The
psychometric Assessment included HDRS the HAS and the GAF scales. Free-T3, Free-T4, TSH,
Thyroid Binding Inhibitory Immunoglobulins (TBII), Thyroglobulin antibodies (TA) and Thyroid
Microsomal Antibodies (TMA) were measured in the serum. The Statistical analysis included 1 and
2-way MANCOVA, discriminant function analysis and Pearson Product Moment Correlation
Coefficient.
Results: All depressive subtypes had significantly higher TBII levels in comparison to controls.
Atypical patients had significantly higher TMA in comparison to controls. No significant correlation
was observed between the HDRS, HAS and GAF scales and thyroid indices. Discriminant function
analysis produced functions based on thyroid indices, which could moderately discriminate
between diagnostic groups, but could predict good response to treatment with 89.47% chance of
success.
Conclusion: Although overt thyroid dysfunction is not common in depression, there is evidence
suggesting the presence of an autoimmune process affecting the thyroid gland in depressive patients
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Background
It is believed that depression might be characterized by a
'low-thyroid function syndrome' [1-3]. Hypothyroidism
might be associated with anxiety [4] or refractory depres-
sion, suggesting that this characterizes one biological sub-
type of refractory depression. However, screening thyroid
tests are often routine for depressed inpatients, and data
suggest that thyroid screening may add little to diagnostic
evaluation. Overt thyroid disease is rare among depressed
inpatients [5], and the role of thyroid hormones in the
pathophysiology of affective disorders remains to be clar-
ified [6].
Depression is traditionally classified into two opposite
poles [7-10], today named 'melancholic' [11] or 'somatic'
syndrome [12] and 'atypical' features, that is 'reverse neu-
rovegetative symptoms' (increased appetite, weight gain,
increased sleep etc) and interpersonal rejection sensitivity
[13-15].
It is reported that in melancholia, the autonomous nerv-
ous system and the stress response seem hyperactive [16].
Patients are anxious, dread the future, lose responsiveness
to the environment, have insomnia, lose appetite, there is
a diurnal variation with depression at its worst in the
morning. Corticotropine Releasing Hormone (CRH) sys-
tem may be hyperactive. On the contrary growth hormone
and reproductive axes may have diminished activities.
Patients with atypical depression present with a constella-
tion of symptoms that seems the antithesis of melancho-
lia [10]. They are lethargic, fatigued, hyperphagic,
hypersomnic, reactive to the environment, and show diur-
nal variation of depression that is at its best in the morn-
ing. Some authors suggest that there is a down-regulated
hypothalamic-pituitary adrenal axis and CRH deficiency
of central origin present in atypical depression [17].
On the other hand, it is suggested that conditions associ-
ated with significant changes in stress system activity, such
as acute or chronic stress or even cessation of chronic
stress, severe exercise, pregnancy, the postpartum period,
and anxiety and mood disorders, may suppress or poten-
tiate autoimmune diseases activity and/or progression
through modulation of the systemic or local pro/antiin-
flammatory cytokine balance [18]. It has been also
reported that patients affected by celiac disease tend to
show a high prevalence of personality and major depres-
sive disorders. Association with subclinical thyroid dis-
ease appears to represent a significant risk factor for these
psychiatric disorders [19,20].
Thus, there is a lot of evidence suggesting the presence of
an underlying autoimmune disorder in unipolar depres-
sion, with the possible involvement of the thyroid gland,
however studies are inconclusive and fail to differentiate
between different clinical subtypes of depression.
The present study aimed to investigate the relationship
between subtypes of unipolar major depression, medium
term (2 years) outcome and thyroid function in patients
and controls. To our knowledge, this is the first study
which explores the possible relationship of DSM-IV
depressive subtypes and the medium term outcome, with
thyroid function.
Methods
Material
Thirty patients (10 males and 20 females) aged 42.43 ±
11.82 years (range 21–60) suffering from Major Depres-
sive disorder according to DSM-IV [11], and 60 normal
controls (25 males and 35 females aged 41,01 ± 9.72 years
(range 25–58) entered the study. Ten patients fulfilled
atypical features (according to DSM-IV), 12 melancholic
features (according to DSM-IV) and 8 did not fulfill crite-
ria for any specific syndrome ('undifferentiated' patients).
Patients and controls were free of any medication for at
least two weeks and were physically healthy with normal
clinical and laboratory findings (Electroencephalogram,
blood and biochemical testing, test for pregnancy, B12
and folic acid).
No patient with catatonic or psychotic features or seasonal
affective disorder was included and no-one fulfilled crite-
ria for another DSM-IV axis-I disorder, except from gener-
alized anxiety disorder and panic disorder. No-one had
history of manic or hypomanic episode in the past, or had
prior history of lithium or thyroid hormones treatment.
The normal control group was composed by members of
the hospital staff, and students. A clinical interview con-
firmed that they did not suffer from any mental disorder
and their prior history was free from mental and thyroid
disorder.
All patients were followed up for a period of 2 years. Dur-
ing that period they received an adequate dose of one or
more antidepressant agent (SSRI or SNRI). According to
their course during that period, they were divided in two
groups: Nineteen (N = 19, 63.33%, 8 melancholics, 5
atypicals, 6 undifferentiated) of them were considered to
be Responders (those with full or almost full remission
and no relapse during the whole 2 year period) and 11
(36.67%, 4 melancholics, 5 atypicals, 2 undifferentiated)
were considered to be partial responders (those with par-
tial attenuation of symptomatology without full remis-
sion or with relapses of episodes). The follow-up was
done in an open naturalistic way.BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/6
Page 3 of 9
(page number not for citation purposes)
All patients and controls provided written informed con-
sent before participating in the study. The protocol was
approved by the Investigational Review Board of the
hospital.
Method
The clinical diagnosis was reached by consensus of two
examiners. The Schedules for Clinical Assessment in Neu-
ropsychiatry version 2.0 [21,22] were directly applied and
the International Personality Disorders Examination [23-
26] was retrospectively applied to the data.
The psychometric assessment included the Hamilton
Depression Rating Scale (HDRS) [27,28], the Hamilton
Anxiety Scale (HAS) [29], and the Global Assessment of
Functioning Scale (GAF) [30].
Assessment of thyroid function
Free-T3 (FT3) was assessed by an AMERLEX-MAB™ Immu-
noradiometric Assay (RIA) kit The sensitivity of the assay
is 0.7 pmol/lt. Normal are values 3.3–8.2. Free-T4 (FT4)
was assessed by an AMERLEX-MAB™ Immunoradiometric
Assay (RIA) kit The sensitivity of the assay is 0.6 pmol/lt.
Normal are values 11–25 pmol/lt. The Thyroid Stimula-
tion Hormone-TSH was assessed with an Ortho-Clinical
Diagnostics™ Immunoradiometric Assay (RIA). The sensi-
tivity of the assay is 0.04 µIU/mlt. The specificity was <
0.001% for FSH, LH and Hcg. Normal values are 0.3–3
mU/lt. Thyroid Binding Inhibitory Immunoglobulins-
TBII were measured with a BRAHMS Diagnostica GmbH
DYNOtest® TRAK human kit Radio Receptor Assay (RRA).
The test has 98.8% sensitivity and 99.6% specificity. The
analytical sensitivity of the assay is 0.3 IU/lt, and the func-
tional assay sensitivity (20% inter-assay variation coeffi-
cient) is 0.9 IU/lt. Normal are values below 10%.
Thyroglobulin antibodies-TA were assessed by a RADIM™
Immuroradiometric Assay (RIA). The analytical sensitivity
of the assay is 15 U/mlt and the functional sensitivity
(with 20% inter assay variation coefficient is 40 IU/mlt.
Normal are values below 100 U/ml. Thyroid Microsomal
Antibodies-TMA (or autoantibodies to Thyroid Peroxi-
dase-anti-TPO) were assessed by a MEDIPAN DIAGNOS-
TICA™ radiolingand assay. The functional assay sensitivity
(10% within assay and 20% between assay variation coef-
ficient) is 35 IU/mlt. Normal are values below 50 IU/ml.
All measurements concern the serum levels of patients.
The ratio FT4/FT3 was also calculated.
Although anti-TPO Ab assay by monoclonal antibody-
assisted RIA appears to be more sensitive and specific for
thyroid autoimmune diseases than other methods [31]
unfortunately it was not available in our laboratory at the
time the study took place.
The statistical analysis included one and two-way Multi-
ple Analysis of Covariance (MANCOVA) with Scheffe as
post-hoc test. Age, the presence of personality disorder
and the presence of anxiety disorder served as covariates.
Two Discriminant function (stepwise method) analyses
were performed with diagnostic group and outcome as
grouping variables and thyroid indices as dependent vari-
ables. Discriminant function analysis produces one func-
tion for each group by using the dependent variables
appropriately weighted. In this way each case obtains a
score (a function of its weighted dependent variables; in
our case of weighted thyroid indices) that corresponds to
every group, and is classified in the group in whose func-
tion obtains the highest score. The forward stepwise
method reduces the number of dependent variables used
in these functions to a minimum. The Pearson Product
Moment Correlation Coefficient was also calculated.
Since 2 MANCOVAs were performed and 21 correlation
coefficients were calculated, the Bonferroni correction led
to the adoption of the p < 0.0021 level (0.05/23 = 0.0021)
as the level for significance for all tests (including post-
hoc tests)
Results
No patient had FT3, FT4, or TA levels outside the normal
range. The plot of FT4 values vs. a logarithmic TSH values
(figure 1) suggests that all depressed patients and controls
are located in the normal reference area, away from pri-
mary hypo- and hyperthyroidism. Four patients (13.3%)
had increased TSH levels (1 melancholic-8.31% and 3
undifferentiated-37.5%), 12 patients (26.6%) had
increased TMA levels (5 atypicals-50%, 6 melancholics-
50% and 1 undifferentiated-11.1%), and 5 (16.6%) had
increased TBII levels (2 atypicals-20% and 3
undifferentiated-37.5%).
Bivariate scatterplot between TSH and FT4 levels Figure 1
Bivariate scatterplot between TSH and FT4 levels. All 
depressed patients are located within the area of non-thyroi-
dal illnessBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/6
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The means and standard deviations for each group are
shown in table 1.
MANCOVA results revealed a main effect for the type of
depression alone (p < 0.001, table 1). Post hoc analysis
(table 2) revealed significant differences between all
depressed subtypes and controls in terms of TBII levels (p
< 0.0021) and between atypicals and controls in terms of
TMA (p < 0.001).
These results should be considered a true effect of the type
of depression since age, the presence of anxiety disorder
and the presence of personality disorder were used as
covariates.
There were no significant correlations between the HDRS,
the HAS and the GAF scales and thyroid indices. No cor-
relation was significant even at p < 0.05.
Discriminant function analysis results are shown in table
3 for depressed subtypes and in table 4 concerning the
short-term outcome.
Discriminant functions may discriminate controls from
depressives with 98.33% accuracy (only one control is
falsely classified) however the success rate is far lower for
depressives (around 60% for all subtypes), however is still
higher than chance (which would be 25% success).
However, the success in discriminating between respond-
ers and poor responders is far higher. The functions suc-
ceeded in an 80.00% correct classification of depressed
patients on the basis of thyroid indices. If we subtract the
two functions, then we obtain the following function:
20.86-1.52*(FT4)-0.98*(TSH)+0.74*(FT3)-0.07*(TBII).
When this function takes values above zero, then the
respected depressed patient is predicted to be a responder
with an 89.47% chance of success. These rates are clearly
higher than the 50% (by chance).
Table 1: 1-way MANCOVA between the diagnostic groups in terms of thyroid results, with age, 2-way MANCOVA between the short 
term outcome (factor 1) and diagnostic groups (factor 2) in terms of thyroid results
Wilks' Lambda Rao's R df 1 Df 2 p-level
1-Way MANCOVA 1: Type of depression
1 0.325 5.052 21 221 0.000
2-Way MANCOVA 1: Outcome 2: Type of depression
1 0.430 2.835 7 15 0.043
2 0.073 5.772 14 30 0.000
12 0.275 1.942 14 30 0.062
Normal
Controls
N = 60
Depressed
patients
N = 30
Atypical
features
N = 10
Melancholic
features
N = 12
Undifferentiated
N = 8
Responders
N = 19
Partial
responders
N = 11
Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D Mean S.D
FT4 16.32 2.69 14.59 1,59 15.50 1.28 14.15 1.45 14.13 1.83 14.04 1.39 15.55 1.52
FT3 6.03 1.56 5.85 1,00 6.57 1.16 5.30 0.50 5.76 0.85 5.83 1.18 5.88 0.61
TS
H
1.31 0.74 1.52 1,21 0.92 0.33 1.42 0.71 2.43 1.92 1.58 0.99 1.43 1.57
TBII 0.89 1.16 8.67 7,93 7.64 3.13 6.31 1.30 13.49 14.41 7.66 2.29 10.40 12.95
TM
A
18.80 3.42 124.8
6
295,
08
272.14 477.
98
51.35 66.9
4
51.04 116.07 151.17 362.54 79.43 111.1
3
TA 15.26 8.52 20.41 9,91 18.23 4.51 23.72 13.9
3
18.19 6.71 19.05 5.71 22.77 14.72
T4/
T3 
rati
o
2.81 0.64 2.54 0,33 2.41 0.39 2.68 0.31 2.46 0.20 2.46 0.35 2.66 0.28
In both analyses, age, the presence of anxiety disorder and the presence of personality disorder as covariates. Scheffe test served as post-hoc test
Table 2: Scheffe Post Hoc test results.
Index Groups compared P
TBII Undifferentiated vs. Normal controls <0.001
Atypicals vs. Normal controls <0.001
Melancholics vs. Normal controls 0.002
TMA Atypicals vs. Normal controls <0.001
Only significant results are shown at p < 0.0021BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/6
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Table 3: Results of Discriminant function analysis (forward stepwise method) with diagnostic groups as the grouping variables.
Rows: Observed classifications
Columns: Predicted classifications
Undifferentiated Atypicals Melancholics Normal controls
% Correct p = 0.088 p = 0.111 p = 0.133 p = 0.666
Undifferentiated 6 2 . 5 0 5111
Atypicals 6 0 . 0 0 0613
Melancholics 5 8 . 3 3 0075
Normal controls 98.33 0 0 1 59
Total 85.56 5 7 10 68
Classification Functions (coefficients)
Undifferentiated Atypicals Melancholics Normal controls
p = 0.088 p = 0.111 p = 0.133 p = 0.666
TBII 1.04 0.57 0.49 0.14
TSH 6.78 4.03 4.47 3.87
TMA 0.01 0.01 0.00 0.00
TA 0.17 0.10 0.25 0.12
FT4 2.39 2.85 2.02 2.73
T4/T3 ratio 2.36 0.45 4.00 2.46
Constant -39.08 -31.56 -29.45 -29.58
The analysis succeeded in a 85.56% correct classification of all cases on the basis of thyroid indices. Only one control was falsely classified. Each case 
is predicted to belong to the group in whose function obtains the highest value. The chance of success of this prediction depends on the group. The 
four groups seems to lie on a continuum with melancholics closer to controls and undifferentiated being the group more distant to controls, and 
atypicals in the middle.
Table 4: Results of Discriminant function analysis (forward stepwise method) with outcome as the grouping variables.
Rows: Observed classifications
Columns: Predicted classifications
Responders Partial responders
% Correct p = 0.633 p = 0.366
Responders 89.47 17 2
Partial responders 63.64 4 7
Total 80.00 21 9
Classification Functions
Responders Partial responders (Responders) -
(Partial Responders)
p = 0.633 p = 0.366
FT4 13.27 14.78 -1.52
TSH 12.21 13.19 -0.98
FT3 0.80 0.06 0.74
TBII 0.37 0.45 -0.07
Constant -106.96 -127.83 20.86
The analysis succeeded in a 80.00% correct classification of depressed patients on the basis of thyroid indices. If we subtract the two functions, then 
we obtain the following function: 20.86-1.52*(FT4)-0.98*(TSH)+0.74*(FT3)-0.07*(TBII). When this function takes values above zero, then the 
respected depressed patient is predicted to be a responder with a 89.47% chance of success.BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/6
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Discussion
The present study reports that while FT3, FT4 and TSH of
depressed patients are generally within the normal range
(figure 1), thyroid binding inhibitory immunoglobulin
levels were higher in depressed patients in comparison to
controls. Microsomal antibodies levels were higher in
atypical patients in comparison to controls. No differ-
ences were detected when depressive subtypes were com-
pared. The way discriminant function analysis classified
depressed patients is interesting. Melancholics are classi-
fied either correctly or as normals, atypicals are classified
either correctly or as melancholics (N = 1) or normals (N
= 3) and finally falsely classified 'undifferentiated'
patients are classified one in each one of the three other
groups. This may mean that melancholics are a more
clearly defined and 'core' group, while atypicals and
undifferentiated patients may constitute groups that fur-
ther deviate away from normality and the 'melancholic
core' of depression. Atypical patients were both more
refractory to treatment and had higher microsomal anti-
bodies (apart from TBII).
Microsomal antibodies are frequently present in patients
with chronic lymphocytic thyroiditis, while thyroid bind-
ing inhibitory immunoglobulines inhibit the binding of
TSH to its receptor, and lead to hypothyroidism.
Depressed patients may have an altered thyroid-stimulat-
ing hormone response to thyrotropin-releasing hormone
(TRH), an abnormally high rate of antithyroid antibodies
and elevated cerebrospinal fluid (CSF) TRH concentra-
tions. Moreover, tri-iodothyronine has been shown con-
clusively to augment the efficacy of various
antidepressants. It has been suggested that the Hypothala-
mus-Pituitary-Thyroid (HPT) axis alterations may be par-
tially trait and partially state markers [32]. Other studies
suggest that depression (and especially bipolar depres-
sion) is characterized by brain hypothyroidism despite
apparent euthyroidism indicated by routine peripheral
blood thyroid hormone results[33,34].
The finding that depression often co-exists with autoim-
mune subclinical thyroiditis suggests that depression may
cause alterations in the immune system, or that in fact it
is an autoimmune disorder itself. Whereas acute stress
may initiate a transient immunologically protective
response, prolonged or poorly controlled psychosocial
stressors may result in depression of different components
of the immune system. These responses may be related to,
or independent of, changes in the neuroendocrine system.
As the rather prolific literature in this infant area of psy-
choneuroimmunology reveals, there are many complex
levels of interaction that require further investigation [35],
concerning a close relationship between delayed hyper-
sensitivity to neural tissue antigens and immunopsychiat-
ric diseases, and they may imply that cell-mediated
immune mechanisms are involved in the pathogenesis of
certain mental disorders [19,20,36].
The availability of thyroid testing led to a bulk of research
on thyroid dysfunction in non-thyroidal illness. Data sug-
gest that within a given patient's status, change of thyroid
function is determined by the severity and duration of ill-
ness as well as the presence of mitigating influences that
are associated with the specific underlying disorders.
These thyroid disturbances in the frame of non-thyroidal
illness is a diagnostic problem which needs focused atten-
tion. Figure 1 represents a graphical solution suggested by
Kaptein[37]. In this figure, it is evident that most
depressed patients are clearly euthyroid, with some of
them falling in the 'non-thyroid illness' area.
There are several papers suggesting that the thyroid func-
tion of depressed patients is within the normal range,
hypothyroidism and hyperthyroidism are extremely
uncommon and that the presence of subtle thyroid func-
tion abnormalities does not have an impact on treatment
outcome [38-43]. However, on the contrary there are even
more papers supporting the idea of a subclinical thyroid
dysfunction, especially in melancholic or refractory
patients, possibly of an autoimmune origin [44-55] sug-
gesting that subclinical hypothyroidism may lower the
threshold for the occurrence of depression[56], or gener-
ally to any mental disorder [57-59]. It is reported that
most patients with depression may have alterations in
their thyroid function including slight elevation of the
serum FT4, blunted TSH response to thyrotropin-releasing
hormone (TRH) stimulation[60], and loss of the noctur-
nal TSH rise and this may reflect brain hypothyroidism in
the context of systemic euthyroidism[61].
Concerning the role thyroid status may play in the aetio-
pathogenesis and neurobiology of depression it has been
suggested that most patients with depression, although
generally viewed as chemically euthyroid, have alterations
in their thyroid function which are generally reversed fol-
lowing alleviation of the depression [61-66].
It is also believed (although not well documented) that
depression is accompanied by various direct and indirect
indicators of a moderate activation of the inflammatory
response system, especially in the frame of the stress-
response activity. Increased production of proinflamma-
tory cytokines, such as interleukin-1, interleukin-6 and
interferon (IFNgamma), may play a crucial role in the
immune and acute phase response in depression[18-
20,67]. On the other hand, it is not known whether
pathophysiological mechanisms other than 5-HT dysreg-
ulation could be involved in TSH blunting in major
depressed patients. Some data suggest that the 5-HTBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/6
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reduced function is more pronounced in those patients
without HPT axis abnormality. In this frame, HPT dysreg-
ulation may be regarded as a compensatory mechanism
for diminished central 5-HT activity[68], which is a
suggestion similar to another one proposed concerning
the Hypothalamus-Pituitary-Adrenal Axis[69]. This just
reflects the fact that the true relationship of peripheral
indices to brain function is always an open question[70].
The most robust relationship between thyroid dysfunc-
tion and depression concerns gestation and the postpar-
tum period. Thyroid antibody-positive women are prone
to hypothyroidism, which is often preceded by transient
hyperthyroidism after delivery[71]. Also, lower range total
and free thyroxine concentrations during late pregnancy
may be related to postpartum depressive symptoms[72].
The presence of abnormal thyroid function tests is not
related with a distinct clinical picture[73]. However,
again, the literature is split and the results are inconclusive
[74-76].
Thus, the review of the literature suggests that there are no
conclusive data on the role of thyroid function in depres-
sion. It is clear that depression is not characterized by an
overt thyroid dysfunction. It is also clear that a subgroup
of depressed patients may manifest subtle thyroid abnor-
malities, or an activation of an autoimmune process,
however the cause of this phenomenon and its implica-
tions are unclear. There is a strong possibility that the
presence of a subtle thyroid dysfunction is a negative
prognostic factor for depression and may demand specific
therapeutic intervention. On the other hand, it should be
stressed that atypical patients are over-represented in the
'partial responders' group of the current study. Thus, the
results of the current study report a triangular relationship
between atypicality, thyroid dysfuction and refractory
depression. It is not possible to arrive at a reliable causal
relationship at this stage. Further focused research is
necessary.
The major advantage of the current study is the follow up
period of 2 years in clearly and solidly diagnosed subtypes
of unipolar major depression. There is no other similar
study in the literature.
The main disadvantage of the study is the relatively small
study population which is at the limit of parametric meth-
ods. Thus, results should be accepted with caution.
Conclusion
The results of the current study, in accord with the litera-
ture, suggest that overt thyroid dysfunction is not com-
mon in depressive patients. No significant differences can
be traced concerning the thyroid function between differ-
ent clinical subtypes of depression nor there is any corre-
lation between specific clinical symptoms and thyroid
indices. This is again in accord with the literature.
Depressed patients had higher Thyroid Binding Inhibitory
Immunoglobulins (TBII), which is suggestive of the pres-
ence of an underlying autoimmune process in depression,
and is independent of the clinical subtype. Response to
treatment could be predicted on the basis of thyroid indi-
ces alone with 89.47% chance of success, which is a rather
high success rate. Further study is necessary in order to
investigate the mechanisms of this process and the extent
of this autoimmune activation.
The current study constitutes only an exploratory effort to
search for the relationship between subtypes of unipolar
depression, thyroid function and clinical outcome. This
effort is restricted both by the study sample as well as from
limitation of the methodology employed. Further
research is essential in order to arrive to solid conclusions.
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